{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:38:00Z","timestamp":1784371080571,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Neuroendocrine tumours (NETs) are rare malignancies characterised by its capacity to synthesise and secrete monoamines, due to its neuroendocrine origin. Its varied locations and symptoms have traditionally been responsible for extended delays in their diagnosis. The interest of this study was to characterise the patient population diagnosed with NETs in Spain and to revise how the disease is managed, together with the hospitalisation costs of these patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The database included records of all patients diagnosed with a NET between 2010 and 2015. Admission records were used to evaluate hospitalisation, disease management data and costs, and single-patient files were used to characterise the population.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Nine Thousand One Hundred Twenty patients were diagnosed with a neuroendocrine tumour between 2010 and 2015, with a 2 fold increase in the diagnosis rate over the study period. 42.25% of the patients were females, while 57.75% were males, and mean diagnosis age was 62.58\u2009years (SD\u2009=\u200914.65). Considering all the registered neuroendocrine neoplasms, 46.86% of the patients had malignant well-differentiated NETs, 32.02% had a malignant poorly differentiated neuroendocrine carcinoma and 42.93% of patients developed metastatic NETs. In addition, 18.59% of patients were diagnosed with benign well-differentiated NETs. The most common tumour sites were the bronchus, lung and other sites, including pancreatic tumours; metastasis was found in the liver and distant lymph nodes. Pancreatic resection was the most common surgical procedure utilised in these patients, summing 19% of total expenses, the injection of an unspecified therapeutic substance (including targeted therapies) was registered in 11.40% of admissions, while chemotherapy was registered in only 6.85% of admissions. The annual healthcare cost of NETs was \u20ac15,373,961, corresponding to \u20ac9092 per patient.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The implementation of standard diagnosis procedures should be prioritised, with a focus on the pancreas and lung, and taking into account that 42.93% of the patients develop a metastatic tumour. The presence of comorbidities and multimorbidities should be considered in order to develop more efficient disease management protocols.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6412-8","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T18:03:00Z","timestamp":1576519380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-0999","authenticated-orcid":false,"given":"Josep","family":"Darb\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Mars\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"12","key":"6412_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002.","journal-title":"Neoplasia."},{"issue":"10","key":"6412_CR2","doi-asserted-by":"publisher","first-page":"E398","DOI":"10.1503\/cmaj.160771","volume":"189","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017;189(10):E398\u2013404.","journal-title":"CMAJ."},{"issue":"11","key":"6412_CR3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.ejca.2013.02.029","volume":"49","author":"JM van der Zwan","year":"2013","unstructured":"van der Zwan JM, Trama A, Otter R, Larra\u00f1aga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565\u201378.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"6412_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3\u20137.","journal-title":"Neuroendocrinology."},{"issue":"4","key":"6412_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397.","journal-title":"Cancer."},{"issue":"1","key":"6412_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JGO.2015.002980","volume":"3","author":"S Singh","year":"2016","unstructured":"Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43\u201353.","journal-title":"J Glob Oncol"},{"issue":"2","key":"6412_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000443168","volume":"103","author":"G Delle Fave","year":"2016","unstructured":"Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for Gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119\u201324.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"6412_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000443169","volume":"103","author":"D O'Toole","year":"2016","unstructured":"O'Toole D, Kianmanesh R, Caplin M. ENETS 2016 consensus guidelines for the Management of Patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103(2):117\u20138.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"6412_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000443170","volume":"103","author":"B Niederle","year":"2016","unstructured":"Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125\u201338.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"6412_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the Management of Patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153\u201371.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"6412_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"6412_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000443166","volume":"103","author":"JK Ramage","year":"2016","unstructured":"Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139\u201343.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"6412_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443165","volume":"103","author":"UF Pape","year":"2016","unstructured":"Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology. 2016;103(2):144\u201352.","journal-title":"Neuroendocrinology."},{"issue":"6","key":"6412_CR14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/ecc.12085","volume":"22","author":"I Chau","year":"2013","unstructured":"Chau I, Casciano R, Willet J, Wang X, Yao JC. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl). 2013;22(6):714\u201325.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"7","key":"6412_CR15","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/ijc.32042","volume":"144","author":"C Vernieri","year":"2019","unstructured":"Vernieri C, Pusceddu S, Fuc\u00e0 G, Indelicato P, Centonze G, Castagnoli L, et al. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). Int J Cancer. 2019;144(7):1704\u201312.","journal-title":"Int J Cancer"},{"issue":"9","key":"6412_CR16","doi-asserted-by":"publisher","first-page":"E293","DOI":"10.3390\/cancers10090293","volume":"10","author":"AP Santos","year":"2018","unstructured":"Santos AP, Santos AC, Castro C, Raposo L, Pereira SS, Torres I, et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors. Cancers (Basel). 2018;10(9):E293.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6412_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00268-015-3341-9","volume":"40","author":"AP Jilesen","year":"2016","unstructured":"Jilesen AP, van Eijck CH, Busch OR, van Gulik TM, Gouma DJ, van Dijkum EJ. Postoperative outcomes of Enucleation and standard resections in patients with a pancreatic neuroendocrine tumor. World J Surg. 2016;40(3):715\u201328.","journal-title":"World J Surg"},{"issue":"6","key":"6412_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3109\/00365521.2014.903432","volume":"49","author":"R Boyar Cetinkaya","year":"2014","unstructured":"Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2014;49(6):734\u201341.","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"6412_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/archsurg.138.8.859","volume":"138","author":"JA Norton","year":"2003","unstructured":"Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138(8):859\u201366.","journal-title":"Arch Surg"},{"issue":"8","key":"6412_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s40273-018-0656-z","volume":"36","author":"C Shen","year":"2018","unstructured":"Shen C, Dasari A, Gu D, Chu Y. S Zhou, Xu Y, et al. costs of cancer care for elderly patients with neuroendocrine tumors. Pharmacoeconomics. 2018;36(8):1005\u201313.","journal-title":"Pharmacoeconomics."},{"issue":"11","key":"6412_CR21","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1245\/s10434-017-5986-0","volume":"24","author":"J Hallet","year":"2017","unstructured":"Hallet J, Law CHL, Cheung M, Mittmann N, Liu N, Fischer HD. Patterns and drivers of costs for neuroendocrine tumor care: a comparative population-based analysis. Ann Surg Oncol. 2017;24(11):3312\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"6412_CR22","doi-asserted-by":"publisher","first-page":"E221","DOI":"10.1503\/cmaj.121349","volume":"185","author":"RA Payne","year":"2013","unstructured":"Payne RA, Abel GA, Guthrie B, Mercer SW. The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: a retrospective cohort study. CMAJ. 2013;185(5):E221\u20138.","journal-title":"CMAJ."},{"issue":"23","key":"6412_CR23","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2012.5265","volume":"307","author":"ME Tinetti","year":"2012","unstructured":"Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition\u2014multimorbidity. JAMA. 2012;307(23):2493\u20134.","journal-title":"JAMA."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6412-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6412-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6412-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:16:17Z","timestamp":1607991377000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6412-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6412"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6412-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data extracted was previously anonymised and, thus, ethics committee approval and patient consent were not required for this study (Ley 14\/2007, de 3 de julio, de Investigaci\u00f3n biom\u00e9dica).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1226"}}